Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease.
Graves' disease
Metabolomics
Myopathy
Senescence
T cells
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
14
10
2021
received:
10
02
2021
accepted:
22
11
2021
pubmed:
1
1
2022
medline:
24
3
2022
entrez:
31
12
2021
Statut:
ppublish
Résumé
Thyroid hormone excess induces protein energy wasting, which in turn promotes muscle weakness and bone loss in patients with Graves' disease. Although most studies have confirmed a relationship between thyrotoxicosis and muscle dysfunction, few have measured changes in plasma metabolites and immune cells during the development and recovery from thyrotoxic myopathy. The aim of this study was to identify specific plasma metabolites and T-cell subsets that predict thyrotoxic myopathy recovery in patients with Graves' disease. One hundred patients (mean age, 40.0 ± 14.2 years; 67.0% female), with newly diagnosed or relapsed Graves' disease were enrolled at the start of methimazole treatment. Handgrip strength and Five Times Sit to Stand Test performance time were measured at Weeks 0, 12, and 24. In an additional 35 patients (mean age, 38.9 ± 13.5 years; 65.7% female), plasma metabolites and immunophenotypes of peripheral blood were evaluated at Weeks 0 and 12, and the results of a short physical performance battery assessment were recorded at the same time. In both patient groups, methimazole-induced euthyroidism was associated with improved handgrip strength and lower limb muscle function at 12 weeks. Elevated plasma metabolites including acylcarnitines were restored to normal levels at Week 12 regardless of gender, body mass index, or age (P trend <0.01). Senescent CD8 Restoring euthyroidism in Graves' disease patients was associated with improved skeletal muscle function and performance, while thyroid hormone-associated changes in plasma acylcarnitines levels correlated with muscle dysfunction recovery. T-cell senescence-related systemic inflammation correlated with plasma acylcarnitine levels and was also associated with small increases in handgrip strength.
Sections du résumé
BACKGROUND
Thyroid hormone excess induces protein energy wasting, which in turn promotes muscle weakness and bone loss in patients with Graves' disease. Although most studies have confirmed a relationship between thyrotoxicosis and muscle dysfunction, few have measured changes in plasma metabolites and immune cells during the development and recovery from thyrotoxic myopathy. The aim of this study was to identify specific plasma metabolites and T-cell subsets that predict thyrotoxic myopathy recovery in patients with Graves' disease.
METHODS
One hundred patients (mean age, 40.0 ± 14.2 years; 67.0% female), with newly diagnosed or relapsed Graves' disease were enrolled at the start of methimazole treatment. Handgrip strength and Five Times Sit to Stand Test performance time were measured at Weeks 0, 12, and 24. In an additional 35 patients (mean age, 38.9 ± 13.5 years; 65.7% female), plasma metabolites and immunophenotypes of peripheral blood were evaluated at Weeks 0 and 12, and the results of a short physical performance battery assessment were recorded at the same time.
RESULTS
In both patient groups, methimazole-induced euthyroidism was associated with improved handgrip strength and lower limb muscle function at 12 weeks. Elevated plasma metabolites including acylcarnitines were restored to normal levels at Week 12 regardless of gender, body mass index, or age (P trend <0.01). Senescent CD8
CONCLUSIONS
Restoring euthyroidism in Graves' disease patients was associated with improved skeletal muscle function and performance, while thyroid hormone-associated changes in plasma acylcarnitines levels correlated with muscle dysfunction recovery. T-cell senescence-related systemic inflammation correlated with plasma acylcarnitine levels and was also associated with small increases in handgrip strength.
Identifiants
pubmed: 34970859
doi: 10.1002/jcsm.12889
pmc: PMC8818593
doi:
Substances chimiques
Methimazole
554Z48XN5E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
355-367Informations de copyright
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
J Clin Endocrinol Metab. 2001 Aug;86(8):3579-94
pubmed: 11502782
Curr Pharm Des. 2013;19(9):1680-98
pubmed: 23061726
Thyroid. 2000 Dec;10(12):1043-50
pubmed: 11201848
BMC Med. 2017 Jan 9;15(1):6
pubmed: 28065164
J Endocrinol. 2017 Feb;232(2):R67-R81
pubmed: 27852725
Thyroid. 2017 Sep;27(9):1109-1117
pubmed: 28699427
J Clin Endocrinol Metab. 1998 Dec;83(12):4269-73
pubmed: 9851762
PLoS One. 2016 Dec 16;11(12):e0165267
pubmed: 27984586
Cell Metab. 2014 Dec 2;20(6):1038-48
pubmed: 25456740
Thyroid. 2008 Feb;18(2):205-16
pubmed: 18279021
Thyroid. 2006 Apr;16(4):375-80
pubmed: 16646684
Clin Immunol. 2007 May;123(2):209-18
pubmed: 17317320
Eur Heart J. 2011 May;32(10):1214-26
pubmed: 21217142
J Cell Biol. 2014 Dec 22;207(6):753-66
pubmed: 25512392
Postgrad Med J. 1968 May;44(511):385-97
pubmed: 4871773
Am J Clin Oncol. 2013 Aug;36(4):354-61
pubmed: 22643561
Mol Cell Endocrinol. 2017 Dec 25;459:79-83
pubmed: 28630021
J Endocrinol. 2014 Feb 10;220(3):305-17
pubmed: 24363450
Thyroid. 1991;1(2):137-41
pubmed: 1688015
Ann N Y Acad Sci. 2004 Nov;1033:158-67
pubmed: 15591013
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
Cell Rep. 2020 Dec 29;33(13):108554
pubmed: 33378671
Cell Death Dis. 2019 Mar 13;10(3):249
pubmed: 30867412
J Gerontol A Biol Sci Med Sci. 2011 May;66(5):548-53
pubmed: 21367961
Clin Endocrinol (Oxf). 1999 Dec;51(6):693-9
pubmed: 10619973
FEBS Lett. 1996 Nov 18;397(2-3):260-2
pubmed: 8955359
J Gerontol A Biol Sci Med Sci. 2017 Oct 1;72(10):1369-1375
pubmed: 28329045
BMC Med. 2017 Nov 30;15(1):210
pubmed: 29187192
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
Horm Metab Res. 2005 Sep;37(9):566-71
pubmed: 16175496
J Clin Endocrinol Metab. 2016 Dec;101(12):5044-5052
pubmed: 27648961
PLoS One. 2010 Jul 12;5(7):e11519
pubmed: 20634953
Front Physiol. 2015 Aug 21;6:237
pubmed: 26347660
Nature. 1977 Nov 3;270(5632):74-6
pubmed: 22048
Thyroid. 2019 Jun;29(6):783-789
pubmed: 30880636
Endocrinol Metab (Seoul). 2013 Dec;28(4):275-9
pubmed: 24396691
N Engl J Med. 2010 Feb 25;362(8):726-38
pubmed: 20181974
J Clin Invest. 1988 Jun;81(6):1695-701
pubmed: 3384946
Proc Natl Acad Sci U S A. 1978 Mar;75(3):1369-73
pubmed: 274725
Thyroid. 2016 Oct;26(10):1422-1430
pubmed: 27465032
J Clin Immunol. 2008 Sep;28(5):464-72
pubmed: 18704663
J Endocrinol. 1994 May;141(2):309-15
pubmed: 8046301
J Immunol. 2011 Nov 15;187(10):5419-28
pubmed: 22013114
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):355-367
pubmed: 34970859